| Entry |
|
|---|
| Name |
Clobazam (JAN/USAN/INN);
Mystan (TN);
Onfi (TN)
|
|---|
| Product |
|
|---|
| Generic |
CLOBAZAM (American Health Packaging), CLOBAZAM (Amneal Pharmaceuticals NY LLC), CLOBAZAM (Amneal Pharmaceuticals NY LLC), CLOBAZAM (Bionpharma), CLOBAZAM (Bionpharma), CLOBAZAM (Breckenridge Pharmaceutical), CLOBAZAM (Cadila Healthcare Limited), CLOBAZAM (Camber Pharmaceuticals), CLOBAZAM (Lupin Pharmaceuticals), CLOBAZAM (Lupin Pharmaceuticals), CLOBAZAM (Micro Labs Limited), CLOBAZAM (Mylan Pharmaceuticals), CLOBAZAM (NorthStar RxLLC), CLOBAZAM (Sandoz), CLOBAZAM (Taro Pharmaceuticals U.S.A.), CLOBAZAM (Taro Pharmaceuticals U.S.A.), CLOBAZAM (Upsher-Smith Laboratories), CLOBAZAM (Upsher-Smith Laboratories), CLOBAZAM (West-Ward Pharmaceuticals Corp.), CLOBAZAM (West-Ward Pharmaceuticals Corp.), CLOBAZAM (Zydus Pharmaceuticals (USA)) |
|---|
| Formula |
C16H13ClN2O2
|
|---|
| Exact mass |
300.0666
|
|---|
| Mol weight |
300.7396
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Class |
Neuropsychiatric agent
DG01567 GABA-A receptor agonist
DG01914 Anxiolytics, benzodiazepine derivatives
DG02036 Antiepileptics, benzodiazepine derivatives
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 1139 |
|
|---|
| Efficacy |
Anticonvulsant, Minor tranquilizer |
|---|
| Disease |
Lennox-Gastaut syndrome [DS: H01813] |
|---|
| Comment |
Benzodiazepine derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576], CYP2C19 [HSA: 1557]
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05B ANXIOLYTICS
N05BA Benzodiazepine derivatives
N05BA09 Clobazam
D01253 Clobazam (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Anticonvulsants
Gamma-aminobutyric Acid (GABA) Augmenting Agents
Clobazam
D01253 Clobazam (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
113 Antiepileptics
1139 Others
D01253 Clobazam (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
Ion channels
Ligand-gated ion channels
GABA (ionotropic)
GABR
D01253 Clobazam (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01253
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01253
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01253
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D01253
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 21
1 C5x C 20.8440 -16.6025
2 C1x C 21.7290 -15.5177
3 C5x C 21.4335 -14.1745
4 N1y N 20.1974 -13.5636
5 N1y N 19.4423 -16.6153
6 C8y C 18.9128 -14.1417
7 C8y C 18.5788 -15.4592
8 C8x C 17.2356 -15.7546
9 C8y C 16.2236 -14.8026
10 C8x C 16.5605 -13.4152
11 C8x C 17.9036 -13.1197
12 X Cl 14.8804 -15.0980
13 O5x O 21.3522 -17.8843
14 C8y C 18.7672 -17.7087
15 C1a C 20.3245 -12.1676
16 O5x O 22.5198 -13.3081
17 C8x C 17.3603 -17.7403
18 C8x C 16.6880 -18.9683
19 C8x C 17.4154 -20.1645
20 C8x C 18.8222 -20.1326
21 C8x C 19.4945 -18.9046
BOND 23
1 3 4 1
2 1 5 1
3 4 6 1
4 2 3 1
5 5 7 1
6 1 2 1
7 6 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 10 11 1
12 6 11 2
13 9 12 1
14 1 13 2
15 5 14 1
16 4 15 1
17 3 16 2
18 14 17 2
19 17 18 1
20 18 19 2
21 19 20 1
22 20 21 2
23 14 21 1
|
|---|
